The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3 kinase inhibitor or pharmaceutically acceptable salt thereof and (b) at least one c Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof for simultaneous separate or sequential administration for the treatment of a proliferative disease particularly a c Met dependent proliferative disease a pharmaceutical composition comprising such combination a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof use of such combination for the treatment of proliferative disease and a commercial package comprising such combination.
